JP2013500015A - シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター - Google Patents

シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター Download PDF

Info

Publication number
JP2013500015A
JP2013500015A JP2012521778A JP2012521778A JP2013500015A JP 2013500015 A JP2013500015 A JP 2013500015A JP 2012521778 A JP2012521778 A JP 2012521778A JP 2012521778 A JP2012521778 A JP 2012521778A JP 2013500015 A JP2013500015 A JP 2013500015A
Authority
JP
Japan
Prior art keywords
sequence
lentiviral vector
cells
virus
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2012521778A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013500015A5 (enExample
Inventor
ジェイムズ エム. アレン,
ホーベン, ニール エス. バン
ジン チョン リ,
デレク ディー. スローン,
トーマス ダブリュー. ジュニア ドゥベンスキー,
Original Assignee
イミューン デザイン コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2013500015(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by イミューン デザイン コーポレイション filed Critical イミューン デザイン コーポレイション
Publication of JP2013500015A publication Critical patent/JP2013500015A/ja
Publication of JP2013500015A5 publication Critical patent/JP2013500015A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001154Enzymes
    • A61K39/001156Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001184Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001184Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001184Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188NY-ESO
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00119Melanoma antigens
    • A61K39/001191Melan-A/MART
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/00119Melanoma antigens
    • A61K39/001192Glycoprotein 100 [Gp100]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001193Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194Prostate specific antigen [PSA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001193Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195Prostate specific membrane antigen [PSMA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/19Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/20Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24Antigen-presenting cells [APC]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/428Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50Colon
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/15011Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141Use of virus, viral particle or viral elements as a vector
    • C12N2770/36145Special targeting system for viral vectors
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012521778A 2009-07-24 2010-07-22 シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター Withdrawn JP2013500015A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22849109P 2009-07-24 2009-07-24
US61/228,491 2009-07-24
PCT/US2010/042870 WO2011011584A1 (en) 2009-07-24 2010-07-22 Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015008415A Division JP6170952B2 (ja) 2009-07-24 2015-01-20 シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター

Publications (2)

Publication Number Publication Date
JP2013500015A true JP2013500015A (ja) 2013-01-07
JP2013500015A5 JP2013500015A5 (enExample) 2013-09-05

Family

ID=42727669

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012521778A Withdrawn JP2013500015A (ja) 2009-07-24 2010-07-22 シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター
JP2015008415A Expired - Fee Related JP6170952B2 (ja) 2009-07-24 2015-01-20 シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター
JP2017005594A Withdrawn JP2017060535A (ja) 2009-07-24 2017-01-17 シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター
JP2018153946A Expired - Fee Related JP6701280B2 (ja) 2009-07-24 2018-08-20 シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2015008415A Expired - Fee Related JP6170952B2 (ja) 2009-07-24 2015-01-20 シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター
JP2017005594A Withdrawn JP2017060535A (ja) 2009-07-24 2017-01-17 シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター
JP2018153946A Expired - Fee Related JP6701280B2 (ja) 2009-07-24 2018-08-20 シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター

Country Status (27)

Country Link
US (3) US20110064763A1 (enExample)
EP (2) EP2456786B2 (enExample)
JP (4) JP2013500015A (enExample)
KR (1) KR101790187B1 (enExample)
CN (1) CN102482329B (enExample)
AU (1) AU2010276194B2 (enExample)
BR (1) BR112012001653A2 (enExample)
CA (1) CA2768938C (enExample)
CY (1) CY1121159T1 (enExample)
DK (2) DK2456786T4 (enExample)
EA (1) EA032403B1 (enExample)
ES (2) ES2455544T5 (enExample)
HR (2) HRP20140327T4 (enExample)
HU (1) HUE043032T2 (enExample)
IL (1) IL217679A (enExample)
LT (1) LT2770061T (enExample)
ME (1) ME01720B (enExample)
MX (1) MX2012001075A (enExample)
NZ (1) NZ597804A (enExample)
PL (2) PL2456786T5 (enExample)
PT (2) PT2456786E (enExample)
RS (2) RS58042B1 (enExample)
SG (1) SG177744A1 (enExample)
SI (2) SI2456786T2 (enExample)
SM (2) SMT201800656T1 (enExample)
TR (1) TR201819229T4 (enExample)
WO (1) WO2011011584A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018508230A (ja) * 2015-01-21 2018-03-29 コーネル ユニバーシティ 異常ヘモグロビン症の予防及び治療のためのウイルスベクター
JP2018537432A (ja) * 2015-11-09 2018-12-20 イミューン デザイン コーポレイション Il−12を発現するレンチウイルスベクターを含む組成物およびその使用法
JP2023535163A (ja) * 2020-07-15 2023-08-16 アンスティテュ・パストゥール Sars-cov-2免疫原性組成物、ワクチン、及び方法

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5828838B2 (ja) * 2009-07-15 2015-12-09 カリミューン, インコーポレーティッド ヒト免疫不全ウイルス阻害のための二重ベクター
CA2826920A1 (en) * 2011-02-15 2012-08-23 Immune Design Corp. Methods for enhancing immunogen specific immune responses by vectored vaccines
EP3632463A1 (en) 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EP3520809B1 (en) * 2012-02-03 2025-08-06 Emory University Immunostimulatory compositions.
US9486539B2 (en) 2012-03-26 2016-11-08 The Regents Of The University Of California Nipah virus envelope pseudotyped lentiviruses and methods of their use
NZ700340A (en) * 2012-03-30 2017-02-24 Immune Design Corp Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign
US9713635B2 (en) * 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
US8323662B1 (en) * 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
SMT201800368T1 (it) 2012-05-16 2018-09-13 Immune Design Corp Vaccini per l'infezione da virus-2 herpes simplex
US20150352228A1 (en) * 2013-01-11 2015-12-10 Bruce TORBET Methods and compositions for enhancing transduction efficiency of retroviral vectors
GB201308772D0 (en) * 2013-05-15 2013-06-26 Imp Innovations Ltd Vectors
SI3116900T1 (sl) 2014-03-09 2021-02-26 The Trustees Of The University Of Pennsylvania Sestavki uporabni pri zdravljenju pomanjkanja ornitin transkarbamilaze(OTC)
US20170196954A1 (en) 2014-07-15 2017-07-13 Immune Design Corp. Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
JP2018504122A (ja) * 2015-01-26 2018-02-15 フェイト セラピューティクス,インコーポレイテッド 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
CN107530410B (zh) 2015-03-18 2021-11-09 欧姆尼赛特有限公司 包含经修饰的α病毒表面糖蛋白与肿瘤相关抗原的融合蛋白及其方法
DK3283658T3 (da) 2015-05-18 2020-05-18 Calimmune Inc Fremgangsmåder til at diskriminere mellem HIV-1 og lentivirus-vektorer
CN108137670A (zh) 2015-09-09 2018-06-08 免疫设计股份有限公司 Ny-eso-1特异性tcr及其使用方法
WO2017083356A1 (en) 2015-11-09 2017-05-18 Immune Design Corp. A retroviral vector for the administration and expression of replicon rna expressing heterologous nucleic acids
AU2017223460A1 (en) * 2016-02-23 2018-09-13 Immune Design Corp. Multigenome retroviral vector preparations and methods and systems for producing and using same
US20180000912A1 (en) * 2016-03-04 2018-01-04 New York University Virus Vectors Expressing Multiple Epitopes of Tumor Associated Antigens For Inducing Antitumor Immunity
WO2017181148A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
IL310729A (en) 2016-04-15 2024-04-01 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
EP3235828A1 (en) * 2016-04-21 2017-10-25 Genethon Stable pseudotyped lentiviral particles and uses thereof
EP3235908A1 (en) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Methods for selectively modulating the activity of distinct subtypes of cells
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
EP3872180A1 (en) 2016-10-20 2021-09-01 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
WO2018148180A2 (en) 2017-02-07 2018-08-16 Immune Design Corp. Materials and methods for identifying and treating cancer patients
WO2018170021A1 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
IL268781B2 (en) 2017-03-16 2025-09-01 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
US11732022B2 (en) 2017-03-16 2023-08-22 Alpine Immune Sciences, Inc. PD-L2 variant immunomodulatory proteins and uses thereof
DK3622079T3 (da) 2017-05-08 2025-11-17 Flagship Pioneering Innovations V Inc Sammensætninger til at gøre membranfusion lettere og anvendelser deraf
EA202090974A1 (ru) 2017-10-18 2020-08-05 Элпайн Иммьюн Сайенсиз, Инк. Вариантные иммуномодулирующие белки лиганда icos и сопутствующие композиции и способы
WO2019136179A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
US11116833B2 (en) * 2018-02-08 2021-09-14 George Mason University Method and system for inactivating virus infectivity for producing live-attenuated vaccines
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
CN112955174A (zh) 2018-07-09 2021-06-11 旗舰先锋创新V股份有限公司 融合剂脂质体组合物和其用途
US12241079B2 (en) 2018-09-14 2025-03-04 The Children's Hospital Of Philadelphia Compositions and methods for hemoglobin production
JP2022513040A (ja) 2018-11-14 2022-02-07 フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド コンパートメント特異的カーゴ送達のための組成物および方法
EP3884043A1 (en) * 2018-11-23 2021-09-29 Vira Therapeutics GmbH Vsv chimeric vectors
CA3120868A1 (en) 2018-11-30 2020-06-04 Alpine Immune Sciences, Inc. Cd86 variant immunomodulatory proteins and uses thereof
US20220364119A1 (en) 2019-06-14 2022-11-17 The J. David Gladstone Institutes, a testamentary trust established under the Will of J.David Gladst Compositions and methods for treating an immunodeficiency virus infection with a therapeutic interfering particle
US20220307050A1 (en) * 2019-08-01 2022-09-29 The Regents Of The University Of California Non-viral transgenesis
CN110982842B (zh) * 2019-12-31 2023-04-18 山西大学 一种慢病毒表达载体的设计及应用
KR20240028975A (ko) 2021-04-08 2024-03-05 사나 바이오테크놀로지, 인크. Cd8-특이적 항체 구조체들 및 이의 조성물
EP4423288A4 (en) * 2021-10-25 2025-09-10 Genvivo Inc COMPOSITIONS AND METHODS OF THERAPEUTIC OR VACCINAL ADMINISTRATION
CN119325517A (zh) * 2022-04-05 2025-01-17 生物辐射实验室股份有限公司 通过数字试验分析病毒颗粒
CA3256953A1 (en) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. VECTORS AND METHODS FOR IN VIVO ANTIBODY PRODUCTION
EP4536836A1 (en) 2022-06-07 2025-04-16 Regeneron Pharmaceuticals, Inc. Pseudotyped viral particles for targeting tcr-expressing cells
WO2025106748A1 (en) * 2023-11-15 2025-05-22 Genvivo, Inc. Compositions and methods for therapeutic delivery

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011636A2 (en) * 2006-07-21 2008-01-24 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4569794A (en) 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
EP0342926B1 (en) 1988-05-17 1994-09-28 Mycogen Plant Science, Inc. Plant ubiquitin promoter system
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5298420A (en) 1990-08-03 1994-03-29 Tanox Biosystems, Inc. Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface
TW279133B (enExample) 1990-12-13 1996-06-21 Elan Med Tech
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
CA2145063A1 (en) 1992-09-22 1994-03-31 Cambridge Genetics Limited Recombinant viruses displaying a nonviral polypeptide on their external surface
US6534051B1 (en) 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
US5279552A (en) 1993-01-11 1994-01-18 Anton Magnet Intradermal injection device
US5997501A (en) 1993-11-18 1999-12-07 Elan Corporation, Plc Intradermal drug delivery device
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5660835A (en) 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
WO1997005266A1 (en) 1995-07-25 1997-02-13 Introgene B.V. Methods and means for targeted gene delivery
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
FR2747046B1 (fr) 1996-04-05 1998-06-19 Univ Paris Curie Nouveaux vaccins issus de plasmovirus
EP0961830A1 (en) 1997-01-29 1999-12-08 Neurosearch A/S EXPRESSION VECTORS AND METHODS FOR $i(IN VIVO) EXPRESSION OF THERAPEUTIC POLYPEPTIDES
US6432699B1 (en) * 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
US6531123B1 (en) 1997-05-01 2003-03-11 Lung-Ji Chang Lentiviral vectors
ZA988446B (en) 1997-09-18 2000-03-22 Res Dev Foundation Production of vaccines using arthropod vectored viruses.
WO1999013905A1 (en) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
US7078483B2 (en) 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
KR20010074493A (ko) * 1998-05-22 2001-08-04 찰스 굿맨 레트로바이러스 전달 시스템
EP1165842A4 (en) * 1999-03-16 2004-07-07 Dana Farber Cancer Inst Inc LENTIVIRAL VECTOR SYSTEM FOR LARGE QUANTITY SCREENING
DK1175497T3 (da) * 1999-04-14 2010-05-31 Novartis Vaccines & Diagnostic Præparater og fremgangsmåder til generering af et immunrespons ved udnyttelse af alfavirusbaserede vektorsystemer
EP1046651A1 (en) 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
WO2001016342A1 (en) 1999-08-27 2001-03-08 The Regents Of The University Of California Use of lentiviral vectors for antigen presentation in dendritic cells
PT1221968E (pt) 1999-10-13 2010-04-16 Novartis Vaccines & Diagnostic Processo de obtenção de respostas imunes celulares de proteínas
US6569143B2 (en) 1999-10-14 2003-05-27 Becton, Dickinson And Company Method of intradermally injecting substances
US20020193740A1 (en) 1999-10-14 2002-12-19 Alchas Paul G. Method of intradermally injecting substances
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US6776776B2 (en) 1999-10-14 2004-08-17 Becton, Dickinson And Company Prefillable intradermal delivery device
US7241275B2 (en) 1999-10-14 2007-07-10 Becton, Dickinson And Company Intradermal needle
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
CA2439620A1 (en) * 2001-03-02 2002-09-12 Merck & Co., Inc. Viral reporter particles
KR100682708B1 (ko) * 2001-06-08 2007-02-15 가부시키가이샤 디나벡크 겐큐쇼 Vsv-g 슈도타입화 원숭이 면역부전 바이러스 벡터를 사용한 영장류 배아 줄기세포로의 유전자 도입
ATE439041T1 (de) 2001-09-13 2009-08-15 California Inst Of Techn Verfahren zur expression von kleinen antiviralen rna-molekülen innerhalb einer zelle
US7737124B2 (en) 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
EP1425400B1 (en) 2001-09-13 2016-11-02 California Institute Of Technology Method for producing transgenic animals
US7195916B2 (en) 2001-09-13 2007-03-27 California Institute Of Technology Method for expression of small antiviral RNA molecules within a cell
AU2002346399A1 (en) 2001-11-14 2003-05-26 Medical Instill Technologies, Inc. Intradermal delivery device and method
DE60328361D1 (de) 2002-02-04 2009-08-27 Becton Dickinson Co Vorrichtung und verfahren zur abgabe oder entnahme einer substanz durch die haut
US7115108B2 (en) 2002-04-02 2006-10-03 Becton, Dickinson And Company Method and device for intradermally delivering a substance
US7047070B2 (en) 2002-04-02 2006-05-16 Becton, Dickinson And Company Valved intradermal delivery device and method of intradermally delivering a substance to a patient
US6780171B2 (en) 2002-04-02 2004-08-24 Becton, Dickinson And Company Intradermal delivery device
EP1499736B1 (en) * 2002-04-26 2009-03-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Improved chimeric glycoproteins and pseudotyped lentiviral vectors
US7455833B2 (en) 2002-07-15 2008-11-25 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids
DE60322070D1 (de) 2002-08-16 2008-08-21 Dept Of Medical Sciences Minis Rekombinante bcg-vakzine
US20040234504A1 (en) 2002-12-18 2004-11-25 Verma Inder M. Methods of inhibiting gene expression by RNA interference
US7090837B2 (en) 2003-01-21 2006-08-15 The Salk Institute For Biological Studies Compositions and methods for tissue specific targeting of lentivirus vectors
US7556814B2 (en) 2003-10-23 2009-07-07 Karp Nelson M Immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) devoid of CD55 and CD59 in the viral membrane
US7108679B2 (en) 2004-03-11 2006-09-19 Becton, Dickinson And Company Intradermal syringe and needle assembly
WO2005113584A1 (en) * 2004-04-29 2005-12-01 Board Of Regents, University Of Texas System Methods and compositions comprising protein l immunoglobulin binding domains for cell-specific targeting
WO2005118802A2 (en) 2004-06-03 2005-12-15 The Regents Of The University Of California Targeting pseudotyped retroviral vectors
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
WO2006031996A2 (en) * 2004-09-14 2006-03-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education Targeting viruses using a modified sindbis glycoprotein
RU2007134371A (ru) * 2005-02-16 2009-03-27 Лентиджен Корпорейшн (Us) Лентивирусные векторы и их применение
WO2006130855A2 (en) 2005-06-01 2006-12-07 California Institute Of Technology Method of targeted gene delivery using viral vectors
ES2657392T3 (es) 2006-09-26 2018-03-05 Infectious Disease Research Institute Composición de vacuna que contiene un adyuvante sintético
US8563523B2 (en) 2007-09-07 2013-10-22 University Of Georgia Research Foundation, Inc. Synthetic lipid A derivative
RS56844B1 (sr) * 2007-12-11 2018-04-30 Univ North Carolina Chapel Hill Retrovirusni vektori sa modifikovanim polipurinskim nizom

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008011636A2 (en) * 2006-07-21 2008-01-24 California Institute Of Technology Targeted gene delivery for dendritic cell vaccination

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
APOLONIA LUIS: "STABLE GENE TRANSFER TO MUSCLE USING NON-INTEGRATING LENTIVIRAL VECTORS", MOLECULAR THERAPY, vol. V15 N11, JPN5012014750, 1 November 2007 (2007-11-01), US, pages 1947 - 1954, ISSN: 0002922871 *
GARDNER J P: "INFECTION OF HUMAN DENDRITIC CELLS BY A SINDBIS VIRUS REPLICON VECTOR IS DETERMINED 以下備考", JOURNAL OF VIROLOGY, vol. V74 N24, JPN5012014749, 1 December 2000 (2000-12-01), pages 11849 - 11857, ISSN: 0002922870 *
MORIZONO K. ET AL., NATURE MEDICINE, vol. 11, no. 3, JPN7015002039, 2005, pages 346 - 352, ISSN: 0003122822 *
YANG LILI: "ENGINEERED LENTIVECTOR TARGETING OF DENDRITIC CELLS FOR IN VIVO IMMUNIZATION", NATURE BIOTECHNOLOGY, vol. V26 N3, JPN5012014748, 1 March 2008 (2008-03-01), ISSN: 0002922872 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018508230A (ja) * 2015-01-21 2018-03-29 コーネル ユニバーシティ 異常ヘモグロビン症の予防及び治療のためのウイルスベクター
JP2018537432A (ja) * 2015-11-09 2018-12-20 イミューン デザイン コーポレイション Il−12を発現するレンチウイルスベクターを含む組成物およびその使用法
JP2023535163A (ja) * 2020-07-15 2023-08-16 アンスティテュ・パストゥール Sars-cov-2免疫原性組成物、ワクチン、及び方法

Also Published As

Publication number Publication date
EP2456786B1 (en) 2014-01-08
SI2770061T1 (sl) 2019-02-28
SG177744A1 (en) 2012-02-28
HK1201557A1 (en) 2015-09-04
EA032403B1 (ru) 2019-05-31
JP2017060535A (ja) 2017-03-30
CA2768938C (en) 2019-05-14
CA2768938A1 (en) 2011-01-27
RS58042B1 (sr) 2019-02-28
SI2456786T1 (sl) 2014-05-30
PL2456786T3 (pl) 2014-06-30
EP2456786B2 (en) 2017-04-19
ES2702274T3 (es) 2019-02-28
LT2770061T (lt) 2018-12-27
SMT201400041B (it) 2014-05-07
US20160076055A1 (en) 2016-03-17
ME01720B (me) 2014-09-20
CN102482329A (zh) 2012-05-30
HRP20140327T4 (hr) 2017-11-03
AU2010276194B2 (en) 2012-02-02
SI2456786T2 (sl) 2017-08-31
PL2770061T3 (pl) 2019-02-28
ES2455544T3 (es) 2014-04-16
PL2456786T5 (pl) 2017-10-31
NZ597804A (en) 2013-10-25
EA201270191A1 (ru) 2012-12-28
EP2770061B1 (en) 2018-10-24
RS53257B (sr) 2014-08-29
PT2770061T (pt) 2018-12-24
SMT201800656T1 (it) 2019-01-11
KR20120068838A (ko) 2012-06-27
EP2770061A1 (en) 2014-08-27
US8187872B2 (en) 2012-05-29
CN102482329B (zh) 2017-11-14
HRP20140327T1 (hr) 2014-05-09
ES2455544T5 (es) 2017-08-16
WO2011011584A1 (en) 2011-01-27
TR201819229T4 (tr) 2019-01-21
AU2010276194A1 (en) 2011-11-24
CY1121159T1 (el) 2020-05-29
JP6170952B2 (ja) 2017-07-26
JP2018198616A (ja) 2018-12-20
US20120039932A1 (en) 2012-02-16
BR112012001653A2 (pt) 2016-11-08
HUE043032T2 (hu) 2019-07-29
DK2456786T3 (en) 2014-03-24
RS53257B2 (sr) 2018-06-29
DK2770061T3 (en) 2019-01-07
IL217679A (en) 2016-09-29
EP2456786A1 (en) 2012-05-30
PT2456786E (pt) 2014-03-25
MX2012001075A (es) 2012-05-22
KR101790187B1 (ko) 2017-10-25
DK2456786T4 (en) 2017-08-07
HRP20181996T1 (hr) 2019-03-22
JP6701280B2 (ja) 2020-05-27
JP2015109853A (ja) 2015-06-18
US20110064763A1 (en) 2011-03-17

Similar Documents

Publication Publication Date Title
JP6170952B2 (ja) シンドビスウイルスエンベロープ糖タンパク質により偽型化したレンチウイルスベクター
CN104583231B (zh) 具有对表达dc-sign的细胞改善的转导效率的慢病毒载体粒子
US8323662B1 (en) Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
US20220088177A1 (en) Retroviral vector for the administration and expression of replicon rna expressing heterologous nucleic acids
HK1170496B (en) Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein
HK1201557B (en) Non-integrating lentiviral vectors
HK1170496A (en) Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150120

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151127

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160115

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20160219

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20160401